DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20160816

Can the mean platelet volume be a predictor of disease activity in primary Sjogren syndrome?

Ahmet Omma, Orhan Kucuksahin, Sevinc Can Sandikci, Bahar Ozdemir, Sukran Erten, Yasar Karaaslan

Abstract


Background: Disease activity in primary Sjogren syndrome (PSS) is measured by the EULAR Sjogren’s syndrome disease activity index (ESSDAI) and patient reported index (ESSPRI). Studies investigating the association between ESSDAI and ESSPRI and previously reported indicators of systemic inflammation are few in the literature. The aim of this study was to determine the clinical utility of the mean platelet volume (MPV) in predicting disease activity in PSS patients.

Methods: A total of 190 subjects including ninety-five PSS patients and ninety-five healthy controls were enrolled. Associations between MPV and other known indicators of systemic inflammation (red cell distribution width (RDW), neutrophil to lymphocyte ratio (NLR) and patient clinical characteristic, ESSDAI and ESSPRI were investigated by using spearman correlation and linear regression analysis.

Results: MPV levels were found to be significantly higher in the PSS group than the control group (10.5±1.2 versus 9.0±1; P<0.001 respectively). Correlation and regression analysis showed a positive correlation between MPV levels and ESSDAI scores (r=0.24, p=0.01). There was a negative correlation between ESSPRI and MPV levels (r=-0.32, p=0.001). NLR and RDW did not show any significant correlation with either ESSDAI or ESSPRI scores.

Conclusions: MPV levels are significantly elevated in PSS patients compared to their control peers, positively correlate with ESSDAI but negatively with ESSPRI scores. MPV might be a useful inflammatory marker to measure disease activity in PSS.

 


Keywords


Primary Sjögren syndrome, Mean platelet volume, Neutrophil/lymphocyte ratio, Disease activity

Full Text:

PDF

References


Cruz-Tapias P, Rojas-Villarraga A, Maier-Moore S, Anaya JM. HLA and Sjogren's syndrome susceptibility. A meta-analysis of worldwide studies. Autoimmun Rev. 2012;11(4):281-7.

Ter Borg EJ, Risselada AP, Kelder JC. Relation of systemic autoantibodies to the number of extraglandular manifestations in primary Sjogren's Syndrome: a retrospective analysis of 65 patients in the Netherlands. Semin Arthritis Rheum. 2011;40(6):547-51.

Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis. 2010;69(6):1103-9.

Seror R, Ravaud P, Mariette X, Bootsma H, Theander E, Hansen A, et al. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. Ann Rheum Dis. 2011;70(6):968-72.

Kavanaugh A. The role of the laboratory in the evaluation of rheumatic diseases. Clin Cornerstone. 1999;2(2):11-25.

Kisacik B, Tufan A, Kalyoncu U, Karadag O, Akdogan A, Ozturk MA, et al. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine. 2008;75(3):291-4.

Hu ZD, Sun Y, Guo J, Huang YL, Qin BD, Gao Q, et al. Red blood cell distribution width and neutrophil/lymphocyte ratio are positively correlated with disease activity in primary Sjogren's syndrome. Clin Biochem. 2014;47(18):287-90.

Mannaioni PF, Di Bello MG, Masini E. Platelets and inflammation: role of platelet-derived growth factor, adhesion molecules and histamine. Inflamm Res. 1997;46(1):4-18.

Uluca U, Ece A, Sen V, Karabel D, Yel S, Gunes A, et al. Usefulness of mean platelet volume and neutrophil-to-lymphocyte ratio for evaluation of children with Familial Mediterranean fever. Med Sci Monit. 2014;20:1578-82.

Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. European Study Group on Classification Criteria for Sjogren's S. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554-8.

Soydinc S, Turkbeyler IH, Pehlivan Y, Soylu G, Goktepe MF, Bilici M, et al. Mean platelet volume seems to be a valuable marker in patients with systemic sclerosis. Inflammation. 2014;37(1):100-6.

Tezcan ME, Demir S, Sargin M, Aliustaoglu M, Goker B. Sjogren's syndrome and mean platelet volume. Reumatismo. 2015;67(1):33-4.

Seror R, Bowman SJ, Brito-Zeron P, Theander E, Bootsma H, Tzioufas A, et al. EULAR Sjogren's syndrome disease activity index (ESSDAI): a user guide. RMD Open. 2015;1(1):e000022.

Risselada AP, Kruize AA, Bijlsma JW. Clinical applicability of the EULAR Sjogren's syndrome disease activity index: a cumulative ESSDAI score adds in describing disease severity. Ann Rheum Dis. 2012;71(4):631.

Hu ZD, Chen Y, Zhang L, Sun Y, Huang YL, Wang QQ, et al. Red blood cell distribution width is a potential index to assess the disease activity of systemic lupus erythematosus. Clin Chim Acta. 2013;425:202-5.

Oehadian ASH, Dewi S, Pramudyo R, Alisjahbana B. The role of neutrophyl lymphocyte count ratio as an inflammatory marker in systemic lupus erythematosus. Acta Med Indones. 2013;45(3):170-4.

Celikbilek M, Dogan S, Ozbakir O, Zararsiz G, Kucuk H, Gursoy S, et al. Neutrophil-lymphocyte ratio as a predictor of disease severity in ulcerative colitis. J Clin Lab Anal. 2013;27(1):72-6.